UNSPSC 51284902: Aztreonam/dextrose

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class AM119. This VA Drug Class (AM119) classifies this compound as belonging to the group BETA-LACTAMS ANTIMICROBIALS, OTHER.

UNSPSC 51284902 Aztreonam/dextrose, a Commodity code, does not reflect the pharmaceutical products state and local governments are actually procuring under this tag. Recent opportunities posted under this code show demand for naloxone (an opioid-overdose reversal medication) and safe drug deactivation systems, along with antibiotics like doxycycline and ciprofloxacin — none of which are aztreonam or dextrose formulations. The mismatch suggests either miscoding in source databases or that this code has been repurposed to cover a broader pharmaceutical supply category. State and local health departments, counties, and community health programs use this code to issue piggyback awards and competitive bids for pharmaceutical inventory, often through consortium vehicles like MMCAP Infuse or direct IFB processes.

Activity appears limited to two recent records: the Illinois Department of Public Health's August 2026 piggyback award to Chartwell Rx LLC for $2,999,999.11 (covering 12 months plus renewal options) for antibiotics under an Invitation for Bid, and Seminole County, Florida's June 2026 IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's Community Health Building in Sanford. The Seminole County procurement noted FEMA potential funding and required e-Verify compliance, workers' compensation insurance, and commercial general liability coverage. Geographic activity is concentrated in Illinois and Florida based on available records. This code shows sparse recent state and local procurement activity, and the products actually being solicited do not align with the code's nominal scope.